Clene Inc CLNN
NASDAQ · United States · Health Technology
$4.03+0.01 (+0.25%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1x1 investor meetings at both conferences. 5th Annual ROTH Healthcare Opportunities ConferenceDate: September 29, 2026Location: New York, NYFormat: 1x1 meetings1x1 Meetings: Please contact your ROTH representative Lytham Partners Investor Conferenc
Investment was led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering was priced at market under Nasdaq rulesProceeds are expected to be sufficient to fund the Company to mid-first quarter 2027, which is beyond the potential FDA decision to accept the CNM-Au8® NDA for review under the accelerated approval pathway SALT LAKE CITY, Sept. 21, 2026
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering priced at market under Nasdaq rulesProceeds are expected to be sufficient to fund the Company to mid-first quarter 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the pricing
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.